Vioxx News
Most Popular Vioxx Story
Forbes to Big Pharma: Fess up
Big Pharma looks more and more like a big ostrich these days, Forbes suggests. The brouhaha over Vytorin and Zetia this week is a case in point. If the controversial Enhance study had proven Vytorin... Read more...
Latest Headlines
- May 27, 2009
- May 19, 2009
- May 14, 2009
- March 24, 2009
- March 19, 2009
- January 23, 2009
- November 12, 2008
- October 14, 2008
- September 10, 2008
- August 28, 2008
- August 19, 2008
- August 12, 2008
- June 4, 2008
- May 30, 2008
- May 21, 2008
- May 5, 2008
- May 2, 2008
- April 21, 2008
- April 18, 2008
- April 16, 2008
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges
